



**Faster insights about a product's safety profile can lead to faster actions. i3 Aperio® is a first-in-class signal detection and assessment tool that leverages i3 Drug Safety's epidemiological expertise and one of the largest post-launch sample populations to date—our proprietary claims database, which contains the health care experiences of millions of individuals—so that users can monitor the safety of new drugs quickly and effectively.**

#### **Real-world data, real-world benefits**

By accelerating the acquisition of real-world information on new prescription drugs, i3 Aperio can help researchers identify signals that could indicate a drug's potential safety issues in near-real time. Data produced by i3 Aperio can enable users to:

- Track a new or existing drug's safety profile in a real-world environment
- Continually improve the post-marketing surveillance of newly approved drugs
- Support research and development decision making
- Put safety signals into a comparative context and permit the exploration of new patterns

#### **Rapid response to safety signals**

When signals arise from Phase IV trials or spontaneous reports, i3 Aperio helps researchers quickly investigate them by providing a denominator to estimate rates as well as a comparison group against which these rates can be evaluated. i3 Aperio offers a complementary approach to the status quo, enabling researchers to corroborate or challenge the validity of the signal rather than continuing to collect spontaneous reports and assess signal strength as new reports accumulate.

Time is of the essence in responding to safety signals, and by using i3 Aperio, evidence-based responses can often be developed in days. i3 Aperio is a cost-effective option for signal evaluation

in comparison with conducting prospective ad hoc research, and for many marketed products provides sufficient sample size for the quantitative evaluation of infrequent events.

#### **Earlier detection of significant trends**

As critical as it is to assess the presence of a suspected safety issue, it's also important to ascertain the absence of safety issues. i3 Aperio data can provide that reassurance and help quantify the prevalence of already-known effects, a capability essential to therapeutic decision making. These and other features distinguish i3 Aperio as a decidedly proactive tool for drug safety evaluation.

#### **Widely applicable findings**

By tracking newly approved drugs in a real-world setting, i3 Aperio makes it possible to detect critical safety signals months or possibly years earlier than other systems currently available. In addition to helping researchers assess the potential risks of both new and existing prescription drugs, i3 Aperio's findings can assist with:

- Refining research and development strategies
- Gaining insight regarding off-label usage
- Measuring compliance and persistency
- Supporting product information changes
- Augmenting Phase IV studies

**Data: integrated, reported, and analyzed**

i3 Aperio is a specialized large-scale registry that provides de-identified patient data at aggregate and drill-down levels. While similar types of data can be obtained through costly clinical trials or traditional registries, i3 Aperio provides data integrated and linked across a variety of sources, including demographics, pharmacy data, health care encounters, and socioeconomic factors. At the click of a mouse, the user receives this critical data linked, reported, and analyzed with descriptive statistics.

**Large and growing database**

i3 Aperio mines a proprietary database containing de-identified integrated medical and pharmacy claims data on millions of individuals—providing a robust, scientifically relevant sample of real-world health care experience that continues to grow in depth and breadth. Data within the i3 Aperio system includes medical claims data from a variety of treatment settings, in-depth pharmacy claims data, laboratory test results, and administrative and demographic information.

**Designed for faster research**

Since the data are derived from an open formulary environment, claims for dispensing newly approved prescription drugs appear soon after their approval. This feature, combined with the solid integration of data collected from several key health care sources, allows i3 Aperio to uniquely collect data that can help researchers identify drug safety signals earlier than before.

Find out how i3 Aperio can speed your drug safety insights.

**Contact us**

US (800) 765 6078

UK + 44 (0) 1628 408408

[info@i3aperio.com](mailto:info@i3aperio.com)

[www.i3aperio.com](http://www.i3aperio.com)